Anthem Biosciences’ initial public offering commenced on a measured note, garnering a subscription of 73% by the close of its opening day. While the offering drew steady interest from retail investors, institutional participation appeared cautious, reflecting broader market sentiments amid global economic uncertainties. The IPO, aimed at fueling the company’s expansion plans and reducing debt, has positioned Anthem as a notable contender in the contract research and manufacturing space.